1291 related articles for article (PubMed ID: 19289438)
41. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
[TBL] [Abstract][Full Text] [Related]
42. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
43. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
44. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer.
Yu HM; Liu YF; Hou M; Liu J; Li XN; Yu JM
Eur J Radiol; 2009 Oct; 72(1):104-13. PubMed ID: 18640802
[TBL] [Abstract][Full Text] [Related]
46. FDG PET-CT in the management of primary breast lymphoma.
Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
[TBL] [Abstract][Full Text] [Related]
47. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
[TBL] [Abstract][Full Text] [Related]
48. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer.
Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J
Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990
[TBL] [Abstract][Full Text] [Related]
49. Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions.
Meirelles GS; Erdi YE; Nehmeh SA; Squire OD; Larson SM; Humm JL; Schöder H
J Nucl Med; 2007 May; 48(5):712-9. PubMed ID: 17475958
[TBL] [Abstract][Full Text] [Related]
50. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
51. The method and efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing the lymphatic metastasis of colorectal carcinoma.
Yu L; Tian M; Gao X; Wang D; Qin Y; Geng J
Acad Radiol; 2012 Apr; 19(4):427-33. PubMed ID: 22265721
[TBL] [Abstract][Full Text] [Related]
52. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature.
Dong MJ; Zhao K; Lin XT; Zhao J; Ruan LX; Liu ZF
Nucl Med Commun; 2008 Sep; 29(9):791-802. PubMed ID: 18677207
[TBL] [Abstract][Full Text] [Related]
53. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
[TBL] [Abstract][Full Text] [Related]
54. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.
Kyoto Y; Momose M; Kondo C; Itabashi M; Kameoka S; Kusakabe K
Ann Nucl Med; 2010 Jun; 24(5):395-401. PubMed ID: 20364373
[TBL] [Abstract][Full Text] [Related]
55. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan.
Chen YM; Huang G; Sun XG; Liu JJ; Chen T; Shi YP; Wan LR
Nucl Med Commun; 2008 May; 29(5):425-30. PubMed ID: 18391725
[TBL] [Abstract][Full Text] [Related]
56. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
Kim SJ; Lee TH; Kim IJ; Kim YK
Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
Sun Y; Duan Q; Wang S; Zeng Y; Wu R
J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
[TBL] [Abstract][Full Text] [Related]
58. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
59. Imaging characteristics of extrapulmonary tuberculosis lesions on dual time point imaging (DTPI) of FDG PET/CT.
Razak HR; Geso M; Abdul Rahim N; Nordin AJ
J Med Imaging Radiat Oncol; 2011 Dec; 55(6):556-62. PubMed ID: 22141602
[TBL] [Abstract][Full Text] [Related]
60. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
